Current status in extracorporeal immunomodulation: Immune disorders

Artificial Organs

Volumn 20, Issue 8, 1996, Pages 902-905

  Bosch, Thomas ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anti neutrophil cytoplasmatic antibodies; Extracorporeal immunomodulation; Immune complexes; Plasma exchange; Sepsis; Systemic lupus erythematosus

Indexed keywords

BIOMATERIALS;

ANTI-NEUTROPHILE CYTOPLASMATIC ANTIBODY; CURRENT STATUS; EXTRACORPOREAL IMMUNOMODULATION; IMMUNE COMPLEX; IMMUNE DISORDERS; IMMUNO MODULATIONS; IMMUNOMODULATORY; PLASMA EXCHANGES; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES;

ARTICLE; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0029814369     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1594.1996.tb04567.x     Document Type: Article

References (22)

1. Gurland HJ, Lysaght MJ, Samtleben W. Immunomodulation: Clinical aspects. Artif Organs 1986;10:122-7.
2. Nydegger U, Späth P, Spycher M. Relevance of proteinaceous exchange fluids for immune complex processing during plasma exchange. In: Valbonesi M, Pineda AA, Biggs FC, eds. Therapeutic Hemapheresis. Wichtig Editore, Milan, Italy, 1986:9-15.
3. Lockwood CM, Worllege S, Path FRC, Nicholas A, Cotton C, Peters DK. Reversal of impaired splenic function in patients with nephritis or vasculitis by plasma exchange. New Engl J Med 1979;300:524-30.
4. Frank MM, Hamburger MI, Lawley TJ, Kimberly RP, Plotz PH. Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. New Engl J Med 1979; 300:518-23.
5. Rosenberg SA, Lotze MT, Muul KM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 1987;316:889-97.
6. Schmidt JL. Thrombotic thrombocytopenic purpura: Successful treatment unlocks etiologic secrets. Mayo Clin Proc 1989;64:956-62.
7. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA, the Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. New Engl J Med 1991;325:393-7.
8. Kiprov DD. Therapeutic plasma exchange in autoimmune disorders. J Clin Apheresis 1993;8:195-210.
9. Hashimoto H, Tsuda H, Kanai Y, Kobayashi S, Hirose S, Shinoura H, Yokohari R, Kinoshita M, Aotsuka S, Yamada H, Takahashi K, Yoshinoya S, Miyamoto T. Selective removal of anti-DNA and anticardiolipin antibodies by adsorbent plasmapheresis using dextran sulfate columns in patients with systemic lupus erythematosis J Rheumatol 1991; 18:545-51.
10. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis in severe lupus nephritis. New Engl J Med 1992;326:1373-9.
11. Schroeder JO, Euler HH, Löffler H. Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann Intern Med 1987;107:344-6.
12. Euler HH, Schroeder JO, Zeuner RA, Teske E. A randomized trial of plasmapheresis and subsequent pulse cyclophosphamide in severe lupus: Design of the LPSG trial, Int J Artif Organs 1991;14:639-46.
13. Euler HH, Schroeder JO, Harten P, Zeuner RA, Gutschmidt HJ. Treatment-free remission in severe lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994;37: 1784-94.
14. Dau PC, Callahan J, Parker R, Golbus J. Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus. J Rheumatol 1991;18:270-6.
15. Johnson JP, Moore J, Austin HA, Balow JE, Antonovych TT, Wilson CB. Therapy of anti-glomerular basement membrane antibody disease: Analysis of prognostic significance of clinical, pathological and treatment factors. Medicine 1985;64:219-27.
16. De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995;25:380-9.
17. Esnault VLM, Testa A, Jayne DRW, Soulillou JP, Guenel J. Influence of immunoadsorption on the removal of immunoglobulin G autoantibodies in crescentic glomerulonephritis. Nephron 1993;65:180-4.
18. Pusey DC, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991;40:757-63.
19. Bucka C, Köhler W, Hertel G, Voigt W, Bennhold I, Schimrigk S, Lange R. Immunoadsorption bei myasthenia gravis. Akt Neural 1993;20:207-13.
20. Shibuya N, Sato T, Osame M, Takegami T, Doi S, Kawanami S. Immunoadsorption therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry 1994;57:578-81.
21. Parillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP. Septic shock in humans: Advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann Intern Med 1990;113: 227-42.
22. Reinke P, Döcke WD, Syrbe U, Lippert J, Zuckermann H, Klug C, von Baehr R, Volk HD. Einsatz von Blutreinigungsverfahren bei sepsis auf der basis neuer erkenntnisse zur immunpathogenese der sepsis. In: Riegel W, ed. Kontinuierliche blutreinigungsverfahren in der Intensivmedizin. Lengerich, Berlin, Germany: Pabst-Verlag, 1994:23-37.